[Efficacy of anti-CD25 monoclonal antibody used in treating steroid-resistant acute graft-versus-host disease following haploidentical bone marrow transplantation].

Abstract

The aim of this study was to investigate the efficacy and feasibility of anti-CD25 monoclonal antibody (basiliximab) in treating steroid-refractory acute graft-versus-host disease (aGVHD) following haploidentical bone marrow transplantation (hiBMT). 15 cases who developed II-IV grade steroid-resistant aGVHD after haploidentical BMT were treated by intravenous injection of basiliximab at a dose of 20 mg on days 1 and 4. In those patients not achieving CR after 1 week, basiliximab injection was repeated. The results showed that 8 cases (53.33%) got complete response (CR). Out of them 4 cases have been still in disease-free survival, 2 cases have been in survival with limited cGVHD, 2 cases died from pulmonary infection; 3 cases (65%) got partial response (PR), out of whom 1 case has been still in disease-free survival, one died from GVHD and infection, and another one died from pulmonary infection; 4 cases without response died from GVHD, pulmonary infection and cardiac failure. Overall response rate was 73.3% and long-term survival rate was 46. 7%. There were no infusion-associated side-effects after treatment with basiliximab. It is concluded that the anti-CD25 monoclonal antibody is efficacious and feasible for steroid-refractory grade II-IV aGVHD after hiBMT, but the overall survival rate is low. Infection is the main cause of death. Thereby, it is especially important to strengthen environmental protection and prevent infection.

• Authors: Jing Liu, Heng-Xiang Wang, Lian-Ning Duan, Hong-Min Yang, Mei Xue, Ling Zhu, Li Ding, Zhi-Dong Wang
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 17 Issue 1 Pg. 160-3 (Feb 2009) ISSN: 1009-2137 [Print] China
• PMID: 19236770 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Hormones
• Interleukin-2 Receptor alpha Subunit
• Recombinant Fusion Proteins
• Basiliximab

Topics

• Adolescent
• Adult
• Antibodies, Monoclonal (therapeutic use)
• Basiliximab
• Bone Marrow Transplantation (adverse effects)
• Child
• Child, Preschool
• Drug Resistance
• Female
• Graft vs Host Disease (drug therapy)
• Hormones (pharmacology)
• Humans
• Interleukin-2 Receptor alpha Subunit (immunology)
• Recombinant Fusion Proteins (therapeutic use)
• Treatment Outcome
• Young Adult